丙烯酸用萃取剂醋酸异丁酯的色谱杂质检测

企业标准（QJ／DF04．01．2501—1999^[1]）规定了丙烯酸用萃取剂-醋酸异丁酯（IBAC）的质量检测方法。该方法要求以聚乙二醇己二酸酯（PEGA）为固定液，用气相色谱法检测IBAC中的杂质醋酸正丁酯（BAC）和异丁醇（IBuOH）。因本分析室不具备PEGA，通过对本分析室几种常用固定液的大量实验，通过选择合适的分析条件，选出了PEGA的代用品。实验结果经验证符合分析要求。另外，对分析方法中的定量方法也做了一些改进。     

膨润土复合丙烯酰胺超强吸水剂的合成与性能研究

为探讨膨润土及其添加量、交联剂量、引发剂量、共聚合温度及中和度对吸水剂吸水性能的影响,采用水溶液聚合的方法,以膨润土和丙烯酰胺为主要原料,N,N'-亚甲基双丙烯酰胺为交联剂,过硫酸铵为引发剂,合成出膨润土复合丙烯酰胺超强吸水剂。该吸水剂吸水倍率和吸盐水倍率分别为920和85倍。     

铁路、公路涂料

水稀释路标漆用固定剂，由其制备的路标漆及其涂覆机；纳米二氧化硅改性水性复合道路标志涂料及其制备方法     

信息与简讯

国外科技检测反渗透系统故障的荧光示踪技术加注防垢剂是解决RO膜面污染的有效和简单方法,然而,防垢剂加注量不足或过份加注会降低RO膜效能和增加运行成本,前者会导致膜面垢的形成,而后者会导致膜面污染。因此,控制防垢剂的剂量对优化RO运行很关键。传统的的检测反渗透系统中防垢剂进液的方法不够精确,慢且不易检测,推荐的荧光技术可克服这些弊病,是精确、低成本的防垢剂控制和检测方法。以荧光物质为基础的跟踪技术在冷却水和锅炉给水处理应用中已比较成熟;现在可将它应用于检测防垢剂剂量和探查RO系统的故障,使RO系统性能优化、降低系…     

基于密度变化的空管二元复合滤棒关键物理参数的检测方法

空管二元复合滤棒具有减害降焦的作用,在卷烟产品中应用广泛。本文提出了一种采用烟支水分密度仪检测空管复合滤棒二元段位置及偏差的方法,分析方法的准确性和精确性,并确定该检测方法下的最小样本量。     

麦穗期不同施药方式下多菌灵残留超标风险研究

通过检测小麦穗期施用多菌灵单剂或其复配剂不同次数、不同施药时间、不同剂量后,小麦籽粒中多菌灵残留量,分析麦穗期不同施药方式下多菌灵残留超标风险。结果表明:多菌灵残留超标风险与施药剂量、次数密切相关。施药次数越多,残留超标风险就越高;施药剂量越大,残留超标风险越高。     

国外专利信息

正钽-银复合电极的制造方法本发明公开了一种制造钽-银复合电极的方法。具体步骤为:(1)制备熔盐;(2)选用耐腐蚀的金属钽作为阳极;(3)选用银基板作为阴极;(4)将阳极和阴极都浸没在熔盐中;(5)采用电镀方法制备钽-银复合电极。镀镍晶粒细化剂自动添加装置本发明公开了一种在镀镍过程中自动添加晶粒细化剂的装置。该装置具有分析功能,定期检测镀镍液     

疏水缔合型阳离子聚丙烯酰胺研究

以甲基丙烯酰氧乙基三甲基氯化铵(DMC)作为阳离子单体,以丙烯酸甲酯作为疏水单体(MA),以丙烯酰胺(AM)为共聚单体,以亚硫酸氢钠和过硫酸铵为常温复合引发剂,以过硫酸铵为高温引发剂,通过溶液聚合制备疏水缔合型阳离子聚丙烯酰胺.通过红外光谱检测分析其结构,结果表明在两种引发体系下生成的聚合物都为AM、DMC和MA的三元共聚物;通过差示扫描量热法(DSC)对其组成和物理性质进行探讨,三元共聚物在70～160℃之间发生玻璃化转变,AM链段在286℃左右发生分解;讨论了不同种类引发剂和不同量引发剂条件下合成的聚合物的黏度,随着引发剂量的增加,聚合物溶液黏度增大,而复合引发体系的低转化率导致其溶液黏度较低.     

三元复合驱垢质分析及防垢研究

本文对油田三元复合驱矿场试验中的垢质的成分进行了定性分析、定量检测,为筛选三元复合驱适宜的防垢剂提供了理论依据。同时针对检测垢型对相应的防垢剂进行了评价。     

戊二醛

戊二醛是有机合成、生物化学、组织化学、细胞化学和微生物学等(?)用的一种重要试剂,广泛用作合成试剂、组织固定剂以及消毒灭菌剂等。本文将简要介绍有关戊二醛的组成、纯度、稳定性、合成方法、纯化、分析方法及在上述领域小的作用机理、影响因素和应用。     

Drug Discovery for Mycobacterium tuberculosis Using Structure-Based Computer-Aided Drug Design Approach

Developing new, more effective antibiotics against resistant Mycobacterium tuberculosis that inhibit its essential proteins is an appealing strategy for combating the global tuberculosis (TB) epidemic. Finding a compound that can target a particular cavity in a protein and interrupt its enzymatic activity is the crucial objective of drug design and discovery. Such a compound is then subjected to different tests, including clinical trials, to study its effectiveness against the pathogen in the host. In recent times, new techniques, which involve computational and analytical methods, enhanced the chances of drug development, as opposed to traditional drug design methods, which are laborious and time-consuming. The computational techniques in drug design have been improved with a new generation of software used to develop and optimize active compounds that can be used in future chemotherapeutic development to combat global tuberculosis resistance. This review provides an overview of the evolution of tuberculosis resistance, existing drug management, and the design of new anti-tuberculosis drugs developed based on the contributions of computational techniques. Also, we show an appraisal of available software and databases on computational drug design with an insight into the application of this software and databases in the development of anti-tubercular drugs. The review features a perspective involving machine learning, artificial intelligence, quantum computing, and CRISPR combination with available computational techniques as a prospective pathway to design new anti-tubercular drugs to combat resistant tuberculosis.     

Synergistic Growth Inhibition of HT-29 Colon and MCF-7 Breast Cancer Cells with Simultaneous and Sequential Combinations of Antineoplastics and CNS Drugs

Several central nervous system (CNS) drugs exhibit potent anti-cancer activities. This study aimed to design a novel model of combination that combines different CNS agents and antineoplastic drugs (5-fluorouracil (5-FU) and paclitaxel (PTX)) for colorectal and breast cancer therapy, respectively. Cytotoxic effects of 5-FU and PTX alone and in combination with different CNS agents were evaluated on HT-29 colon and MCF-7 breast cancer cells, respectively. Three antimalarials alone and in combination with 5-FU were also evaluated in HT-29 cells. Different schedules and concentrations in a fixed ratio were added to the cultured cells and incubated for 48 h. Cell viability was evaluated using MTT and SRB assays. Synergism was evaluated using the Chou-Talalay, Bliss Independence and HSA methods. Our results demonstrate that fluphenazine, fluoxetine and benztropine have enhanced anticancer activity when used alone as compared to being used in combination, making them ideal candidates for drug repurposing in colorectal cancer (CRC). Regarding MCF-7 cells, sertraline was the most promising candidate alone for drug repurposing, with the lowest IC₅₀ value. For HT-29 cells, the CNS drugs sertraline and thioridazine in simultaneous combination with 5-FU demonstrated the strongest synergism among all combinations. In MCF-7 breast cancer cells, the combination of fluoxetine, fluphenazine and benztropine with PTX resulted in synergism for all concentrations below IC₅₀. We also found that the antimalarial artesunate administration prior to 5-FU produces better results in reducing HT-29 cell viability than the inverse drug schedule or the simultaneous combination. These results demonstrate that CNS drugs activity differs between the two selected cell lines, both alone and in combination, and support that some CNS agents may be promising candidates for drug repurposing in these types of cancers. Additionally, these results demonstrate that 5-FU or a combination of PTX with CNS drugs should be further evaluated. These results also demonstrate that antimalarial drugs may also be used as antitumor agents in colorectal cancer, besides breast cancer.     

丁醇母液回收利福平工艺的研究

利福平又称利福霉素SV或甲哌利福霉素,是半合成的抗结核病抗生素,具有广谱抗菌作用,临床上多与其他抗结核药物合并使用,疗效显著,对结核分枝杆菌、革兰氏阳性菌和部分革兰氏阴性菌都有抑菌或杀菌作用,主要用于耐药结核植菌和耐药金葡菌的感染,亦用于抗麻风病治疗。粗品利福平母液中含较高含量的利福平,本文以溶酶萃取法回收母液中的利福平,选取合理、有效的溶剂确定最佳的回收工艺路线,以提高产品的收率,并解决环保问题。     

Host–guest interactions in tetramethyl-cucurbit[6]uril with anti-tuberculosis drug isoniazid

A novel supramolecular host–guest complex of anti-tuberculosis drug isoniazid (INH) with symmetrical α,α′,δ,δ′-tetramethyl-cucurbit[6]uril (TMeQ[6]) has been investigated using ¹H NMR spectroscopy methods, mass spectrometer and single-crystal X-ray diffraction analysis. The result revealed that the INH guest is located the portal of the TMeQ[6] host in both the solutions and the solid state. The driving forces for the association between the guest INH and the host TMeQ[6] are made by a balance between hydrogen bonding interactions and ion-dipole interactions.     

Bioinformatics Identification of Drug Resistance-Associated Gene Pairs in Mycobacterium tuberculosis

Tuberculosis is a chronic infectious disease caused by Mycobacterium tuberculosis (Mtb). Due to the extensive use of anti-tuberculosis drugs and the development of mutations, the emergence and spread of multidrug-resistant tuberculosis is recognized as one of the most dangerous threats to global tuberculosis control. Some single mutations have been identified to be significantly linked with drug resistance. However, the prior research did not take gene-gene interactions into account, and the emergence of transmissible drug resistance is connected with multiple genetic mutations. In this study we use the bioinformatics software GBOOST (The Hong Kong University, Clear Water Bay, Kowloon, Hong Kong, China) to calculate the interactions of Single Nucleotide Polymorphism (SNP) pairs and identify gene pairs associated with drug resistance. A large part of the non-synonymous mutations in the drug target genes that were included in the screened gene pairs were confirmed by previous reports, which lent sound solid credits to the effectiveness of our method. Notably, most of the identified gene pairs containing drug targets also comprise Pro-Pro-Glu (PPE) family proteins, suggesting that PPE family proteins play important roles in the drug resistance of Mtb. Therefore, this study provides deeper insights into the mechanisms underlying anti-tuberculosis drug resistance, and the present method is useful for exploring the drug resistance mechanisms for other microorganisms.     

桂皮酰氯及其酯的制法

目的:利用拼合原理,以桂皮酸为原料,与相关活性的药物成酯得到衍生物,以期得到活性更高的药物.方法:以桂皮酸为起始原料,经酰氯化、成酯等反应,得到目标化合物.结论:通过实验得到了桂皮酰阿魏酸酯和桂皮酰水杨酸酯,产率分别达到89.5%和85.98%.产品通过熔点测定法、薄层色谱法、红外光谱法及化学鉴别方法等对其进行了初步验证.     

安定类药物的研究进展

简述了安定类药物的起源、临床应用、副作用及最新的分析方法。指出安定类药物既有较好的治疗作用,也有毒副作用,因此应当尽量减少其用量。     

Fiber-Based Composite Tissue Engineering Scaffolds for Drug Delivery

Drug delivery through tissue-engineered scaffolds provides a composite approach to address the regenerative limitations of simple material implantation, providing expanded avenues for therapeutic tissue-repair strategies in the clinic. Both nano- and microfibrous scaffolds generated by a variety of techniques have been investigated for their potential in drug-delivery applications. While nanofibers mimic the structure and organization of natural extracellular matrix, microfibers provide more sustained release of drugs, larger pores to facilitate cell infiltration, and improved mechanical support. Various methods exist to embed drugs within the fiber matrix to modulate the release kinetics specific to the tissue-engineering application. The current article reviews the established and emerging fabrication methods for drug-loaded fiber-based scaffolds and addresses how further combination into composite scaffolds can enhance drug delivery and tissue regeneration.     

手性药物的液相色谱分析

手性药物的HPLC分析是药物分析中较新的研究领域,综述了近年来手性药物色谱分离的研究进展。对手性衍生化试剂法和手性固定相法的分离机理、检测方法、试剂种类和应用等作了介绍。     

Combination Therapy to Treat Fungal Biofilm-Based Infections

An increasing number of people is affected by fungal biofilm-based infections, which are resistant to the majority of currently-used antifungal drugs. Such infections are often caused by species from the genera Candida, Aspergillus or Cryptococcus. Only a few antifungal drugs, including echinocandins and liposomal formulations of amphotericin B, are available to treat such biofilm-based fungal infections. This review discusses combination therapy as a novel antibiofilm strategy. More specifically, in vitro methods to discover new antibiofilm combinations will be discussed. Furthermore, an overview of the main modes of action of promising antibiofilm combination treatments will be provided as this knowledge may facilitate the optimization of existing antibiofilm combinations or the development of new ones with a similar mode of action.